Abstract: This article presents a new self-tuning sinusoidal recursive controller (STSRC) for handling the uncertainties and disturbances in a three-phase grid-connected photovoltaic system (GCPVS).

How Recursion is leading a new era of AI-driven drug discovery AI drug discovery is not a new phenomenon – but it is evolving at an almost dizzying pace. Recursion is one of the earliest innovators in ...

The above button links to Coinbase. Yahoo Finance is not a broker-dealer or investment adviser and does not offer securities or cryptocurrencies for sale or facilitate trading. Coinbase pays us for ...

Recursion is building an industrialized engine for medicine. It operates among biotech stocks, selling access to its proprietary platform and pursuing joint development with major partners like Roche ...

Recursion's co-founder and long-serving chief executive, Chris Gibson, has switched to the role of company chair, and will be succeeded in the CEO role by R&D and commercial head Najat Khan. The ...

The companies at the frontier of artificial intelligence should be ready to slow down, one of the fastest-moving among them says. Anthropic, the maker of the Claude chatbot, has claimed AI systems may ...

RSI is also defined as an “AI system capable of fully autonomously designing and developing its own successor,” per Anthropic’s blog post. “We are not there yet, and recursive self-improvement is not ...

Christopher Gibson, Co-Founder and CEO, announced, "beginning January 1, the amazing Najat Khan is going to take over the role of CEO, President and Director of Recursion." Gibson will transition to ...

Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings.

Forbes contributors publish independent expert analyses and insights. Dr. Lance B. Eliot is a world-renowned AI scientist and consultant. This voice experience is generated by AI. Learn more. This ...

Recursion Pharmaceuticals has not confirmed its next earnings publication date, but the company's estimated earnings date is Tuesday, August 4th, 2026 based off last year's report dates. Learn more on ...

During the previous two years, 321 institutional investors and hedge funds held shares of Recursion Pharmaceuticals. The most heavily invested institutionals were Vanguard Group Inc. ($193.00M), ARK ...